| 000 | 01789 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250518031129.0 | ||
| 264 | 0 | _c20190624 | |
| 008 | 201906s 0 0 eng d | ||
| 022 | _a1791-2431 | ||
| 024 | 7 |
_a10.3892/or.2019.7068 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBright, S A | |
| 245 | 0 | 0 |
_aSelected nitrostyrene compounds demonstrate potent activity in chronic lymphocytic leukaemia cells, including those with poor prognostic markers. _h[electronic resource] |
| 260 |
_bOncology reports _cMay 2019 |
||
| 300 |
_a3127-3136 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xchemistry |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xgenetics |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 | _aDrug Screening Assays, Antitumor |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInhibitory Concentration 50 |
| 650 | 0 | 4 |
_aLeukemia, Lymphocytic, Chronic, B-Cell _xblood |
| 650 | 0 | 4 | _aLeukocytes, Mononuclear |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNitro Compounds _xchemistry |
| 650 | 0 | 4 | _aPrimary Cell Culture |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aPurines _xpharmacology |
| 650 | 0 | 4 |
_aQuinazolinones _xpharmacology |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 650 | 0 | 4 |
_aStyrenes _xchemistry |
| 700 | 1 | _aByrne, A J | |
| 700 | 1 | _aVandenberghe, E | |
| 700 | 1 | _aBrowne, P V | |
| 700 | 1 | _aMcelligott, A M | |
| 700 | 1 | _aMeegan, M J | |
| 700 | 1 | _aWilliams, D C | |
| 773 | 0 |
_tOncology reports _gvol. 41 _gno. 5 _gp. 3127-3136 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3892/or.2019.7068 _zAvailable from publisher's website |
| 999 |
_c29502312 _d29502312 |
||